Home » Drug Information » FDA Approved Drugs » 1997
Medical Areas: Dermatology | Infections and Infectious Diseases
View By:YearCompanyConditionsTherapeutic AreasDrug Names
Mentax (1% butenafine HCl cream)
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Approval Status: Approved January 1997
Treatment Area: tinea corporis (ringworm) and tinea cruris (groin fungus)
Mentax has been approved for the treatment of tinea corporis
(ringworm) and tinea cruris (groin fungus).
Tinea pedis, tinea corporis, and tinea cruris account for the
vast majority of all skin fungal infections. Most skin fungus
treatments available in the United States are fungistatic, which
only arrest fungus growth. In contrast, in vitro studies
demonstrate that Mentax is a potent fungicidal compound rather than
only being fungistatic.
Clinicians at several major medical conferences have reported
that Mentax, when dosed just once per day, is highly effective in
reducing the clinical signs and symptoms of skin fungus with only a
very low incidence of side effects. The drug has been evaluated in
multi-center, vehicle-controlled, parallel, randomized,
double-blind efficacy trials in over 1,300 subjects. Mentax
achieved highly significant statistical results in these trials,
eliminating fungi from tinea lesions in 90 percent of subjects.